Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Liraglutide: Evidence Summary
Evidence summary for Liraglutide across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Liraglutide overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Type 2 diabetes (glycemic control) | Tier A | 100 | Multiple Phase 3 RCTs (LEAD program) demonstrate 1.1-1.4% HbA1c reduction |
| Chronic weight management | Tier A | 10 | SCALE trial showed 8.4% weight loss; FDA-approved indication |
| Cardiovascular risk reduction | Tier A | 1 | LEADER CVOT (n=9,340) showed 13% MACE risk reduction |
| NASH/NAFLD | Tier B | 5 | Moderate RCT evidence for liver fat reduction |